About Sophie Dessureault
Board Certified in Surgery
Works for Specialty Center
Hyperthermic Intraperitoneal Chemotherapy
Dessureault was the surgeon involved in Moffitt’s recent groundbreaking study that detailed the benefits to patients of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy, also known as HIPEC.
Patients who returned for a second round of treatment in the study survived almost three times as long as those who underwent only one procedure.
As a surgeon in the department of gastrointestinal oncology, her clinical and research interests also include vaccines that focus on reversing tumor-induced immune suppression.
Dessureault serves as associate professor at the University of South Florida’s College of Medicine. She first arrived at the school in 1999 for a fellowship in surgical oncology. She has won the Society of Surgical Oncology Young Investigator Award and the American Society of Clinical Oncology Career Development Award.
She graduated from the Dalhousie University School of Medicine in Halifax, Nova Scotia. She did a surgical residency at the University of Toronto, where she also completed a doctorate in the surgical scientist program and graduated as valedictorian of her class.See More Top Mesothelioma Doctors
Disclaimer: Dr. Sophie Dessureault has no professional affiliation with Asbestos.com.
2 Cited Article Sources
Moffitt Cancer Center. (n.d.). Sophie Dessureault, MD, PhD.
Retrieved from: https://moffitt.org/providers/sophie-dessureault/
- U.S. News & World Report. (n.d.). Dr. Sophie Dessureault. Retrieved from: https://health.usnews.com/doctors/sophie-dessureault-432865
How did this article help you?
What about this article isn’t helpful for you?
Did this article help you?
Share this article
Last Modified October 9, 2019